OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
Join us on 7 October 2021 to discover the most cutting-edge technologies and use of data driving the rapid developments within psychedelic medicine. Learn from industry leaders and pioneers who are at the forefront of this crucial – and exponential – period of development.
Through our concise half-day programme, we will be showcasing the latest data and technology in this exciting sector, alongside expanding businesses looking for capital – delivering the industry’s most promising opportunities directly to investors & funds.
Every PSYCH Investor Summit is an opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier.
For Sponsorship & Media enquires contact our team.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS
PSYCH | Investor Summit: Europe & Asia – What Can Europe & Asia Learn From North America
PSYCH | Investor Summit: Europe & Asia – The Future of Psychedelic Medicine in Europe
PSYCH | Investor Summit: Europe & Asia – Psychedelic Patents & I.P.
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS AND INSIGHTS
EXCLUSIVE: Field Trip’s Co-founder and Executive Chairman Ronan Levy on Investor Opportunities Following Nasdaq Listing
Field Trip will join the Nasdaq exchange on 29 July and become the first psychedelic company to list on Nasdaq’s Global Select Market, having met the stringent financial requirements for the stock exchange’s top tier. The eagerly anticipated uplisting is the latest in a series of significant company announcements. In February, Field Trip signed aContinue reading
Biden Calls for Lower Drug Prices: Should Psychedelics Investors be Concerned?
At the start of July, US President Joe Biden signed an executive order to drive down prescription drug prices, with a wide-reaching impact across healthcare, but should investors in psychedelic medicine be concerned? The government hopes to increase competition through the directive, in a market where Americans pay 2.5 times more for treatments than theContinue reading
Data Science Driving Innovation in Psychedelic Medicine
Big data has revolutionised healthcare, enhancing treatment safety, efficacy and operational efficiency. The technology has become crucial to accelerate drug discovery and development, underpinning the clinical trials that demonstrate psychedelic medicines’ groundbreaking potential. Study results indicate significantly improved patient outcomes, which will instigate further investigations to treat associated disorders, with digital innovation a vehicle toContinue reading
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
